William F. Fearon

May 8, 2024 | jamanetwork.com | Celina M. Yong |William F. Fearon

One could argue that the most shocking finding across decades of large clinical trials that deeply investigate coronary revascularization is that women are still poorly represented in them. Cardiovascular disease (CVD) is the number 1 cause of death among both men and women in the US, yet decades of cardiovascular clinical trials have persistently enrolled a predominantly male population.